However, there's a new symptom: conjunctivitis. India was the first country to detect Arcturus. The highly contagious and new COVID-19 strain is in at least 24 countries. According to experts ...

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

the MHLW is an important milestone for the saRNA field and the Arcturus/CSL alliance, which has candidates against other variants in phase 3 testing – including the prevailing XBB.1.5 strain ...

Arcturus Therapeutics believes it’s “highly ... run two phase 3 studies of its mRNA vaccine against different strains of bird flu, as well as bring four new influenza vaccines into phase ...

Arcturus Therapeutics and CSL's COVID-19 vaccine ... 1 subtype of Omicron variant BA.2.86, which is still one of the main strains currently circulating in Europe. The lipid nanoparticle-formulated ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...

Arcturus Therapeutics Holdings Inc. (the ... for up to 12 months post vaccination against multiple SARS-CoV-2 strains in both younger and older adult age groups versus the mRNA comparator.